4-nitro-N-{(2R)-2-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]propyl}-N-pyridin-2-ylbenzamide hydrochloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4-nitro-N-{(2R)-2-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]propyl}-N-pyridin-2-ylbenzamide hydrochloride
• 英文别名: N-[(2R)-2-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]-4-nitro-N-pyridin-2-ylbenzamide;hydrochloride
• 化学式: C₂₇H₂₉N₅O₅*ClH
• 分子量: 540.019
• InChiKey: KUAROPKTVCTEDP-VEIFNGETSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.04
• 重原子数：
  38
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  104
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  1-(2,3-二氢-1,4-苯并二烷-5-基)哌嗪盐酸盐 在 potassium carbonate 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 78.0h， 生成 4-nitro-N-{(2R)-2-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]propyl}-N-pyridin-2-ylbenzamide hydrochloride
  参考文献：
  名称：

  Synthesis and Biological Evaluation of Benzodioxanylpiperazine Derivatives as Potent Serotonin 5-HT_1A Antagonists:  The Discovery of Lecozotan

  摘要：

  A series of benzodioxanylpiperazine derivatives possessing a 4-aryl amide substituent was prepared and evaluated for 5-HT1A affinity and functional antagonist activity in vitro and in vivo. All of the compounds in this series possessed high affinity for the human 5-HT1A receptor and many displayed potent antagonist activity in vitro and varying degrees of intrinsic activity in vivo. Compound 11c (Lecozotan) was selected for further development and is currently in clinical trials.

  DOI：

  10.1021/jm049493z

文献信息

• Synthesis and Biological Evaluation of Benzodioxanylpiperazine Derivatives as Potent Serotonin 5-HT_1A Antagonists:  The Discovery of Lecozotan
  作者：Wayne E. Childers,、Magid A. Abou-Gharbia、Michael G. Kelly、Terrance H. Andree、Boyd L. Harrison、Douglas M. Ho、Geoffrey Hornby、Donna M. Huryn、Lisa Potestio、Sharon J. Rosenzweig-Lipson、Jean Schmid、Deborah L. Smith、Stacey J. Sukoff、Gan Zhang、Lee E. Schechter

  DOI：10.1021/jm049493z

  日期：2005.5.1

  A series of benzodioxanylpiperazine derivatives possessing a 4-aryl amide substituent was prepared and evaluated for 5-HT1A affinity and functional antagonist activity in vitro and in vivo. All of the compounds in this series possessed high affinity for the human 5-HT1A receptor and many displayed potent antagonist activity in vitro and varying degrees of intrinsic activity in vivo. Compound 11c (Lecozotan) was selected for further development and is currently in clinical trials.